Target intelligence / Profile preview

Epithelial membrane protein 2 (EMP2)

Target
EMP2
Molecular classification
Tetraspan membrane protein, PMP22/EMP family, Tetraspanin superfamily (TM4SF)
01

Overview

EMP2 is a tetraspan membrane protein (∼160 amino acids, four transmembrane domains) of the PMP22/EMP family, highly expressed in lung, skin, esophagus, and retina. It localizes to lipid raft microdomains, where it acts as a scaffold for adhesion molecules (integrins, ICAM-1), modulates cell surface composition, and regulates membrane organization, migration, endocytosis, proliferation, and signaling. EMP2 is crucial for neutrophil migration in lungs, cell adhesion, and immune modulation. Dysregulated EMP2 expression is linked to multiple cancers and nephrotic syndromes, and it is actively being explored as a therapeutic target and biomarker in oncology.

Other names
EMP2PMP22/EMP family memberTM4SF member (tetraspanin superfamily)
02

Mechanism of action

Therapeutic inhibition or modulation of EMP2 disrupts its coordination of protein trafficking and adhesion molecule display, thereby impairing cell adhesion, migration, and signaling essential for tumor growth and metastasis. EMP2 also regulates integrin trafficking and caveolin signaling.

03

Biological functions

Cell membrane organizationCell signalingCell proliferationCell adhesionCell migrationEndocytosisApoptosis/cell deathCholesterol homeostasisEmbryo implantationAngiogenesisImmune response regulation (PMN/Neutrophil migration)
04

Disease associations

Cancer (including endometrial, glioblastoma, breast, ovarian)Nephrotic syndrome type 10 and Hereditary Steroid-Resistant Nephrotic SyndromeInflammation (via PMN trafficking in lungs)Vascular disease/angiogenesis
05

Safety considerations

Disruption of normal cell adhesionDisruption of immune cell migration (notably in lung tissue)Possible kidney filtration disruptionModulation may affect vascular integrityModulation may affect embryo implantation
06

Interacting drugs

Specific drugs directly targeting EMP2 are in preclinical and early clinical investigation phases for cancer

3 more in the full profile.

07

Biomarkers

EMP2 expression as a biomarker for cancer diagnosisEMP2 expression as a biomarker for cancer prognosisEMP2 expression as a biomarker for patient selection (especially in endometrial and brain cancers)

Beyond the preview

Go deeper on Epithelial membrane protein 2 (EMP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epithelial membrane protein 2 (EMP2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call